Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Nab-paclitaxel,"Any cancer, following grade 3+ hypersensitivity reaction on paclitaxel",Nab-paclitaxel,Only if cost neutral or cost saving,,Oncology Agents and Immunosuppressants
